Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection

Cyril B Dousson

Abstract
This review describes the current state of discovery of past most important nucleoside and nucleotide prodrugs in the treatment of hepatitis C virus infection as well as future potential drugs currently in discovery or clinical evaluation. I highlight first generation landmark prodrug compounds which have been the foundations of incremental improvements toward the discovery and approval milestone of Sofosbuvir. Sofosbuvir is the first nucleotide prodrug marketed for hepatitis C virus treatment and the backbone of current combination therapies. Since this approval, new nucleotide prodrugs using the same design of Sofosbuvir McGuigan prodrug have emerged, some of them progressing through advanced clinical trials and may become available as new incremental alternative hepatitis C virus treatments in the future. Although since Sofosbuvir success, only minimal design efforts have been invested in finding better liver targeted prodrugs, a few novel prodrugs are being studied and their different modes of activation may prove beneficial over the heart/liver targeting ratio to reduce potential drug–drug interaction in combination therapies and yield safer treatment to patients. Prodrugs have long been avoided as much as possible in the past by development teams due to their metabolism and kinetic characterization complexity, but with their current success in hepatitis C virus treatment, and the knowledge gained in this endeavor, should become a first choice in future tissue targeting drug discovery programs beyond the particular case of nucleos(t)ide analogs.

Keywords
Hepatitis C virus, nucleoside analogs, nucleotide analogs, prodrugs, NS5B

Introduction
According to a recent report, in 2015 globally, an estimated 71 million people were living with chronic hepatitis C infection accounting for 1% of the world population, with only 20% knowing their infection status. Mortality was still increasing and an estimated 1.75 million new HCV infections occurred worldwide in 2015. Infection with HCV becomes chronic in most infected persons and a person may be infected with HCV for as long as 30 years or more before developing any clinical symptoms of disease and 20% or more develop life-threatening end-stage chronic liver disease, such as cirrhosis or hepatocellular carcinoma. In 2015, HCV led to 411,000 deaths.

The research for more effective HCV treatments has developed and advanced significantly in the recent years and the focus on direct-acting antiviral agents (DAAs) and specially nucleotide prodrugs having a broad genotypic coverage and high barrier to resistance have emerged as the best promise for backbone combination to eradicate HCV in the next decade.

Nucleo(s)tide prodrugs are pharmacologically inactive modified analogs able to be transformed in vivo to their parent nucleo(s)tide via metabolic or chemical processes occurring in the body. For the purpose of clarity, I will here use under the generic “prodrug” term only “carrier prodrugs” (covalently bound chemical entity releasing the “drug” by hydrolytic cleavage at the target site) and not bioprecursors.
(chemical entity metabolized into the pharmacologically active entity) as defined elsewhere.  

This review will cover the different main current and future prodrugging strategies used with the more significant reported active nucleo(s)tides which landmark the field of HCV. Comprehensive reviews of nucleos(t)ide prodrugs have been reported elsewhere.  

**A-nucleoside prodrugging**

Both nucleosides and nucleotides can be prodrugged depending on the shortcoming properties one wants to overcome.

Nucleoside prodrugging is performed on a nucleoside that can be efficiently metabolized to its active triphosphate (TP) in order to overcome bioavailability or tissue targeting shortcomings. The more common oral bioavailability issues are usually due to lack of permeation through biological membranes (lipophilicity is too low) and the prodrug design will mask or counterbalance the polar functions of the parent nucleoside (e.g. iso-butyryl esters of Balapiravir), or taking advantage of amino acid active transport (e.g. L-valine ester of Valopicitabine); solubility, which is less common with nucleoside analogs, but can be mitigated by prodrugging with polar or ionizable pro-moieties (e.g. valine esters); Addressing tissue targeting topics can be more complex as the required enzymatic pro-moiety cleavage in a specific tissue can be different from one parent nucleoside analog to another as well as species dependent.

The first nucleoside prodrug evaluated in clinical trials for HCV was NM283 from Idenix (Figure 1), a 3'-L-valine ester of its parent nucleoside NM107 setting the scene in HCV therapies with the most used 2'C-Me sugar modification. The valine ester substituent was chosen to improve poor bioavailability of NM107 when given orally.  

NM283 was shown in later clinical phases to be not stable enough in the gastrointestinal (GI) tract, leading to GI side effects and was discontinued.  

Other first generation prodrugs followed with Balapiravir and Mericitabine, both tri- and di-iso-butyryl esters, respectively, of their corresponding nucleoside (Figure 1).  

None of these first generation nucleoside prodrugs led to sufficient clinical benefit to allow approval of a simple nucleoside prodrug, because daily dose normalized viral load reductions were too low (Table 1).  

**B-nucleotide prodrugging**

On the other hand, nucleotide prodrugging is usually performed to overcome 5'-monophosphorylation problem or to improve liver targeting. As opposed to nucleoside prodrugging, the advantage in HCV activity of a 5'-monophosphate prodrug can be demonstrated in cell culture experiments as shown in Table 2.  

1. SATE-phosphoramidate prodrugs

The first clinical proof of concept for such kind of nucleotide prodrugs was reported by Idenix with the discovery of IDX184 (Scheme 1).  

Other nucleotide prodrugs were then reported based on the 2'C-Me well-known sugar backbone with different prodrug moieties giving various improvements over the parent nucleoside. IDX184 is a benzylamine/“SATE” phosphoramidate prodrug which benefits from a thioester enzymatic cleavage liberating the corresponding carboxylic acid and the 2-thioethyl side chain which undergoes self emulating cleavage. While ethylene sulfide was proposed as a cleavage metabolite, it has been shown that this metabolite was not found in vivo, but glutathione adduct was instead formed. The benzylamine phosphoramic acid is further cleaved by a phosphoramidase to yield the 5'-monophosphate. Further metabolism by cellular kinases gives the active corresponding TP (Scheme 1).  

IDX184 improved dramatically the clinical dose efficiency as over a two weeks once a day 100 mg dose
In December 2013, the clinical proof of concept of GS-7977, other groups have used similar McGuian prodrug as exemplified by BMS-986094, AL-335, ACH-3422, and MIV-802 to reduce the development risk associated with the metabolites formed by the pro-moieties (l-alanine and phenol). The cleavage and release of these pro-moieties in vivo have been well characterized for GS-7977 or other analogs bearing the same prodrug stereochemistry.

The first step involves hydrolysis of the carboxylic ester by cathepsin A (Cat A) and carboxylesterase 1 followed by an intramolecular cyclization of the carboxylate on the phosphorus atom, displacing the phenolate and followed by water hydrolysis of the unstable cyclized intermediate to yield the alanyl phosphoramidic acid metabolite which is further hydrolyzed by the enzyme hHint 1 to the nucleoside-monophosphate (NMP). In the case of GS-7977, this NMP is then phosphorylated by UMP-CMP kinase to its nucleoside-diphosphate (NDP), and final phosphorylation by Nucleoside DiPhosphate Kinase (NDPK) affords its nucleoside-triphosphate (Scheme 2).

### Table 1. Clinical dose efficiency of HCV nucleoside and nucleotide prodrugs.

| Prodrug | Daily dose | Viral load reduction (log10) at end of treatmenta | Dose normalized viral load reduction (log10/g) |
|---------|------------|---------------------------------------------|---------------------------------------------|
| NM28312–15 (Valopicitabine) | 800 mg | 1.2 (2 wk treatment) | 1.5 |
| R162616 (Balapiravir) | 3000 mg | 1.2 (2 wk treatment) | 0.4 |
| R712817 (Mericitabine) | 3000 mg | 2.7 (2 wk treatment) | 27.0 |
| IDX18418 | 100 mg | 2.7 (2 wk treatment) | 27.0 |
| GS-7977 (Sofosbuvir)19,20 | 400 mg | 4.7 (1 wk treatment) | 11.8 |
| BMS-98609421 | 100 mg | 2.53 (1 wk treatment) | 25.3 |
| AL-33522 (Adafosbuvir) | 800 mg | 4.00 (1 wk treatment) | 5.0 |
| ACH-342223 | 700 mg | 3.4 (1 wk treatment) | 4.9 |
| IDX21437 (MK-3682/Uprifosbuvir)24 | 300 mg | 4.23 (1 wk treatment) | 14.1 |

HCV: hepatitis C virus.
aGenotype 1 patients.

### Table 2. HCV activity in cell culture experiments.

| Compound | EC50 (µM)a | Prodrug EC50 improvementb | CC50 (µM) | SI |
|----------|------------|--------------------------|-----------|----|
| NM28326  | 7.600      | 0.3                      | >100      | >13|
| Balapiravir27 | 1.100       | 1.2                      | >1000     | >909|
| Mercicitabine28–30 | 0.850       | 0.7                      | >100      | >118|
| IDX18431 | 0.203      | 16                       | >75       | >370|
| Sofosbuvir16,32,33 | 0.092       | >1087                    | >100      | >1087|
| GS-093834 | 0.144       | 67                       | >100      | >694|
| BMS-98609420 | 0.010      | 580                      | 7         | 700|
| IDX1936835 | 0.160       | 36                       | >100      | >613|
| AL-33536  | 0.075      | NR                       | >100      | >1333|
| ACH-342237 | 0.050       | NR                       | >25       | >500|
| MIV-80238  | 0.045      | >1111                    | >100      | >2222|
| IDX2143739 | 56.800     | 1                        | >100      | >2 |

HCV: hepatitis C virus; NR: Not reported.
aGenotype 1b replicon assay.
bFold change EC50 nucleoside/EC50 prodrug activity (improvement of the prodrug versus parent nucleoside).

2. McGuian prodrugs

GS-7977 (Sofosbuvir) is a McGuian phosphoramide-date prodrug (l-alanine/phenol) originally developed by Pharmasset and is to date the only nucleotide prodrug which has received approval for HCV treatment in December 2013. After the clinical proof of concept of GS-7977, other groups have used similar McGuian prodrug as exemplified by BMS-986094, AL-335, ACH-3422, and MIV-802 to reduce the development risk associated with the metabolites formed by the pro-moieties (l-alanine and phenol). The cleavage and release of these pro-moieties in vivo have been well characterized for GS-7977 or other analogs bearing the same prodrug stereochemistry.

The first step involves hydrolysis of the carboxylic ester by cathepsin A (Cat A) and carboxylesterase 1 followed by an intramolecular cyclization of the carboxylate on the phosphorus atom, displacing the phenolate and followed by water hydrolysis of the unstable cyclized intermediate to yield the alanyl phosphoramidic acid metabolite which is further hydrolyzed by the enzyme hHint 1 to the nucleoside-monophosphate (NMP). In the case of GS-7977, this NMP is then phosphorylated by UMP-CMP kinase to its nucleoside-diphosphate (NDP), and final phosphorylation by Nucleoside DiPhosphate Kinase (NDPK) affords its nucleoside-triphosphate (Scheme 2).

BMS-986094 is a McGuian prodrug that was designed to improve in vitro activity in the replicon assay owing to an increase of the lipophilicity by using a naphthol in place of the usual phenol, substituting the shorter iso[propyl ester with a neo[pentyl and by removing a hydrogen bond donor on the guanine base with a 6 methoxy analog. These structural modifications improved the replicon EC50 with activities as low as 10 nM but with a cytotoxic value CC50 of 7 µM giving a selectivity index (toxicity/activity) of 700 (Table 2). BS-986094 phase II clinical trial was stopped due to a fatal cardiac adverse effect that was characterized further as a mitochondrial toxicity mainly due to its TP and to a lesser extent to its...
The effect of neopentyl ester prodrug of BMS-986094 in place of the isopropyl ester present in Sofosbuvir can be clearly seen in a previous study by McGuigan et al., where these two esters were synthesized with the same nucleoside backbone and tested. The isopropyl ester analog of BMS-986094 proved to be over 14 times less toxic in the Huh7 cells, so some of the toxicity of BMS-986094 can be attributed to its neopentyl ester modification. It has also been reported by Deval et al., with another comparable pair of compounds by making the BMS-986094-monophosphate prodrug on Sofosbuvir nucleoside. The Sofosbuvir-modified hybrid had an increase in the cell toxicity assay of Huh7 and U937 cells compared to Sofosbuvir.

*potential structure from corresponding references30, 31, 32
Three other McGuigan prodrugs still in clinical development are AL-335, ACH-3422, and MIV-802 for which little preclinical data have been reported but for which the HCV replicon activity is similar or slightly better than Sofosbuvir (Table 2). The early virologic load decrease in patients is much less efficient than Sofosbuvir (Table 1) for the first two more advanced candidates (AL-335 and ACH-3422), and it was recently announced that AL-335 would not be developed further.54 Although one cannot exclude that MIV-802 or ACH-3422 could potentially progress further in combination with other DAAs.

3. Cyclic phosphotriester (CPO) prodrugs

The 3',5'-CPO prodrug structural unit shows possible significant improvements on the medicinal chemistry perspective, allowing smaller molecular weight and therefore better ligand efficiency as well as lower number of rotational bonds which, with the former property, may both provide enhanced passive diffusion through cell membrane. Both GS-0938 and IDX19368 (Figure 3) are actually double prodrugs as they bear the ethoxy masking group on the 6-guamine base position allowing a better solubility of these guanosine derivatives. The in vivo metabolism was studied in the case of GS-0938 and is described in Scheme 3. It involves a first oxidative cleavage by cytochrome (CYP3A4), followed by opening of the cyclic 3',5'-phosphodiester (CPOH) by phosphodiesterase, the last step being the hydrolysis of the 6-ethoxy guanine prodrug by adenosine deaminase-like protein 1.55

4. D-amino acid based aryl-phosphoramidate prodrugs (PON)

IDX21437 is a D-amino acid phosphoramidate prodrug of the well-established HCV active 2'-β-modified ribonucleoside family. As seen in Table 2, it has a very different profile in cell culture experiments, compared to other clinical candidates, due to the unnatural amino acid configuration part of its prodrug, giving a lack of activity in the HCV replicon system and would therefore not be viewed by classical medicinal chemists as a promising compound. But actually, this compound displayed an unexpectedly good in vivo profile in regards to its ability to form high levels of its corresponding active TP in animal liver, the target organ for HCV. The metabolism of IDX21437 was reported and proved to require a different enzymatic system for the initial cleavage compared to McGuigan prodrug Cat A involvement (Scheme 4).39 The different enzymes involved in the metabolism of D-amino acid phosphoramidate is supposed to be responsible for the better liver to heart selectivity, as D-alanylate phosphoramidic acid metabolite was not observed in heart cells.44 Currently, IDX21437 (now MK-3682) is progressing in phase II combination studies.

5. Other miscellaneous prodrugs

Other HCV nucleotide prodrugs were reported in early discovery studies as CC-1845 from Cocrystal, for which the structure is unknown but likely
a McGuigan prodrug of 2\(^\prime\)C-Me-2,6,-disubstituted purine analog. However, recently the company has declared that preclinical studies indicated higher than acceptable toxicity and have now switched to a backup compound CC-2850.56

**Conclusion**

From the first nucleosides through the first generation of their prodrugs to the second generation of nucleotide prodrugs demonstrating increasing added value of liver targeting in HCV, no new simple nucleosides or their prodrugs would be further developed but favoring their nucleotide prodrugs as can be seen by the latest candidates in discovery or ongoing clinical evaluation. With the knowledge gathered by the different metabolism pathways of pro-moieties, future nucleotide prodrugs will be designed toward more elaborated and tissue targeted drugs with single or multiple prodrugs and possible combinations of the above well characterized and main classes of prodrugs as can be already seen in recent patent applications in the HCV and other disease areas. I can envision for the future of HCV nucleos(t)ide drugs better liver targeting based on more specific liver metabolism, compared to other tissues as exemplified by IDX21437, rather than first path metabolism effect as observed in the earlier per os prodrug design. HCV nucleotide drug discovery has been a tremendous scientific emulation for the last 15 years and will be able to serve as a foundation case

---

**Scheme 3.** CPO prodrug metabolism.

**Scheme 4.** D-amino acid phosphoramidate prodrug IDX21437 and its proposed metabolism.
for other disease area nucleos(t)ide prodrug development as well as, more broadly, prodrug targeting example for other class of drugs in the future.

Acknowledgments
The author wishes to thank Dr Gilles Gosselin for his invaluable assistance in reviewing this manuscript.

Declaration of conflicting interests
The author is an employee of Idenix, an MSD company.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Cyril B Dousson http://orcid.org/0000-0002-6046-5032.

References
1. Global Hepatitis Report 2017. Geneva: World Health Organization, 2017. Licence: CC BY-NC-SA 3.0 IGO.
2. Krečmerová M. Amino acid ester prodrugs of nucleoside and nucleotide antivirals. Mini Rev Med Chem 2017; 17: 818–833.
3. Sofia MJ. Nucleotide prodrugs for the treatment of HCV infection. In: E De Clercq (ed) Advances in pharmacology. 1st ed. Vol. 67. Oxford (UK): Academic Press, 2013, pp. 39–73.
4. Bobeck D, et al. Advances in nucleoside monophosphate prodrugs as anti-HCV agents. Antivir Ther 2010; 15: 935–950.
5. Coats SJ, et al. Chutes and ladders in hepatitis C nucleoside drug development. Antiviral Res 2014; 102: 119–147.
6. Zhang Y, et al. Current prodrug strategies for improving oral absorption of nucleoside analogues. Asian J Pharm Sci 2014; 9: 65–74.
7. Pradere U, et al. Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem Rev 2014; 114: 9154–9218.
8. Mehelly Y. The protides boom. ChemMedChem 2016; 11: 1114–1116.
9. Mehelly Y, et al. The protide prodrug technology: from the concept to the clinic. J Med Chem. Epub ahead of print 9 August 2017. DOI: 10.1021/acs.jmedchem.7b00734.
10. Pierra C, et al. Synthesis and pharmacokinetics of Valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem 2006; 49: 6614–6620.
11. Idenix press release, 13 July 2007, https://www.thefreereybrary.com/Valopicitabine+Development+Program+Placed+on+Clinical+Hold+in+the...a0166344307 (accessed 7 February 2018).
12. Afdhal N, et al. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 2004; 40: 726A.
13. Toniutto P, et al. Valopicitabine dihydrochloride: a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs 2007; 8: 150–158.
14. Zhou XJ, et al. Pharmacokinetics and pharmacodynamics of valopicitabine. J Hepatol 2005; 42: 229.
15. Afdhal N, et al. Enhanced antiviral efficacy for valopicitabine (NM283) plus PEG-Interferon in hepatitis C patients with HCV genotype-1 infection: results of a phase IIa multicenter trial. J Hepatol 2005; 42: 39–40.
16. Roberts S, et al. Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV patients. J Hepatol 2006; 44: S269.
17. Berrey M, et al. R7128 14-day monotherapy study results for the treatment of chronic Hepatitis C. In: Fifty-eighth AASLD, Boston, USA, 200–6 November 2007, late-breaker abstr., http://www.natap.org/2007/AASLD/AASLD_02.htm (accessed 7 February 2018).
18. Lalezari J, et al. A phase IIa study of IDX184 in combination with pegylated interferon (PegIFN) and ribavirin (RBV) in treatment-naive HCV genotype-1-infected subjects. Oral presentation on Sunday, October 31st at 3:45 p.m., In: AASLD, Boston, USA, 29 October–2 November 2010.
19. Guedj J, et al. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: Sofosbuvir (GS-7977) and GS-0938. Antivir Ther 2014; 19: 211–220.
20. Lawitz E, et al. Once daily dual nucleotide combination of PSI-938 and PSI-7977 provides 94% HCVRNA <LOD at day 14: first purine/pyrimidine clinical combination data (the NUCLEAR study). J Hepatol 2011; 54: S543.
21. Rodriguez-Torres M, et al. Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7-days of oral therapy in naive genotype-1 chronic HCV patients. In: The Liver Meeting, Sixty-second AASLD, San Francisco, USA, 4–8 November 2011, abstr. 354, Hepatology, 54(4) SUPPL:535A, October 2011.
22. Berlih E, et al. AL-335, a once-daily pangenotypic nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naive genotype 1–4 patients. J Hepatol 2016; 64: S404–S405.
23. Gane E, et al. ACH-3422, a novel nucleotide prodrug inhibitor of HCV NS5B polymerase. J Hepatol 2015; 62: S277.
24. Gane E, et al. A phase I/IIa study assessing 7-day dosing of MK-3682 (formerly IDXR12437) in subjects infected with hepatitis C virus (HCV). In: AASLD, Boston, USA, 7–11 November 2014, http://www.natap.org/2014/AASLD/AASLD_34.htm (accessed 7 February 2018).
25. Brown N. Progress towards improving antiviral therapy for Hepatitis C with Hepatitis C virus polymerase inhibitors. Part I: nucleoside analogues. Expert Opin Investig Drugs 2009; 18: 709–725.
26. Gardelli C, et al. Phosphoramidate prodrugs of 2'-C-methylthymidine for therapy of hepatitis C virus infection. J Med Chem 2009; 52: 5394–5407.

27. Klumpp K, et al. The novel nucleoside analog R1479 (4'-azidoctydine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 2006; 281: 3793–3799.

28. Ali S, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NN5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother 2008; 52: 4356–4369.

29. McCown MF, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52: 1604–1612.

30. Deval J, et al. Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2'-fluoro-4'-chloromethyl-cytidine triphosphate. PLoS Pathog 2015; 11: e1004995.

31. Deshpande M, et al. Highly active nucleoside derivative for the treatment of HCV. Patent application US2014/0309189, USA, 16 October 2014.

32. Sofia M, et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleoside prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010; 53: 7202–7218.

33. Ma H, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-d-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species. J Biol Chem 2007; 282: 29812–29820.

34. Idenix unreported data. EC_{50} (n = 8).

35. Pierra Rouviere C, et al. Design, synthesis and antiviral evaluation of 2'-C-methyl branched guanosine nucleotides: the discovery of IDX19368, a potent inhibitor of HCV replication. unpublished internal report June 2017.

36. Tan H, et al. Preclinical characterization of AL-335, a potent uridine based nucleoside polymerase inhibitor for the treatment of chronic hepatitis C. Poster P0682, April 23rd 2015, In: EASL, Vienna, Austria, 22–26 April 2015.

37. Huang M, et al. ACH-3422, a novel HCV NS5B RNA polymerase nucleotide inhibitor, demonstrates improved potency over Sofosbuvir against HCV genotype-3 replicons in vitro. Oral presentation on November 11th 2014, In: AASLD, Boston, USA, 7–11 November 2014.

38. Lindqvist A, et al. Preclinical characterization of MV-802, a novel uridine nucleoside HCV NS5B polymerase inhibitor, for treatment of hepatitis C virus infection. Poster P0682, April 23rd 2015, In: EASL, Vienna, Austria, 22–26 April 2015.

39. Alexandre F-R, et al. The discovery of IDX21437: design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine nucleotides as potent liver-targeted HCV polymerase inhibitors. Bioorg Med Chem Lett. 2017;27(18): 4323-4330.

40. Zhou XJ, et al. Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of Hepatitis C virus, in healthy subjects. Antimicrob Agents Chemother 2011; 55: 76–81.

41. Lalezari J, et al. Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic Hepatitis C virus infection. Antimicrob Agents Chemother 2012; 56: 6372–6378.

42. Szun G, et al. Design, synthesis and antiviral evaluation of 2'-C-methyl branched guanosine pronucleotides: the discovery of IDX184, a potent liver-targeted HCV polymerase inhibitor. Future Med Chem 2015; 7: 1675–1700.

43. Ständering D. IDX184 and novel nucleotides for the treatment of HCV. Oral presentation on August 8th 2012, In: Twentieth international round table on nucleosides, nucleotides and nucleic acids, Montreal, Canada, 8 August 2012.

44. Lagrutta A, et al. Cardiac drug-drug interaction between HCV-NS5B pronucleotide inhibitors and amiodarone is determined by their specific diastereocchemistry. Sci Rep 2017; 7: 44820.

45. Kalayanov G, et al. Nucleotide derivatives which are HCV inhibitors for use in the treatment of hepatitis C. September 9th 2016, Patent application WO2016/140615.

46. Andersson M. Nucleotide phosphoramidate formulation. September 9th 2016, Patent application WO2016/140616.

47. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204671Orig1s000Approv.pdf (accessed 7 February 2018).

48. Murakami E, et al. Mechanism of activation of PSI-7851 and its diastereomer PSI-7977. J Biol Chem 2010; 285: 34337–34347.

49. Furman PA, et al. Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antivir Res 2011; 91: 120–132.

50. Shah R, et al. Caught before released: structural mapping of the reaction trajectory for the Sofosbuvir activating enzyme, human histidine triad nucleotide binding protein 1 (hHint1). Biochemistry 2017; 56: 3559–3570.

51. McGuigan C, et al. Dual pro-drugs of 2'-C-methyl guanosine monophosphate as potent and selective inhibitors of Hepatitis C virus. Bioorg Med Chem Lett 2011; 21: 6007–6012.

52. McGuigan C, et al. Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for Hepatitis C virus bioavailability. J Mol Med Berlin 2016; 94: 1363–1377.

53. Jin Z, et al. Structure-activity relationship analysis of the nucleoside-ns5b (accessed 7 February 2018).

54. Janssen press release, 11 September 2017. Janssen to continue-hepatitis-c-development-program (accessed 7 February 2018).

55. McGuigan C, et al. Design, synthesis and antiviral evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for Hepatitis C virus. Bioorg Med Chem Lett 2010; 20: 4850–4854.

56. Du J, et al. β-D-2'-α-F-2'. βC-Methyl-6-O-substituted 3',5'-cyclic phosphate nucleotide prodrugs as inhibitors of Hepatitis C virus replication: a structure-activity relationship study. Bioorg Med Chem Lett 2012; 22: 5924–5929.

57. http://www.cocrystalpharma.com/product-pipeline/nucleoside-ns5b (accessed 7 February 2018).